Zealand Pharma AS (OTCPK:ZLDPF)
$ 42.89 (0%) Market Cap: 3.02 Bil Enterprise Value: 847.50 Mil PE Ratio: 3.17 PB Ratio: 1.38 GF Score: 62/100

Zealand Pharma A/S at Goldman Sachs Healthcare Conference Transcript

Jun 09, 2026 / 05:20PM GMT
Release Date Price: $42.03 (+7.91%)
Rajan Sharma
Goldman Sachs Group Inc - Analyst

Good afternoon, everyone. Thanks for joining us. My name is Rajan Sharma, European pharma and biotech analyst here at Goldman Sachs. Very pleased to have Zealand Pharma with us and Adam Steensberg, CEO, Adam, thank you. Thanks for joining.

I know that you've been on the road with ADA. So thanks for adding on this to the trip.

Adam Steensberg;S;President
Zealand Pharma A;Chief Executive Officer, Member of the Executive Management

/- -

Pleased to be here.

Questions & Answers

Rajan Sharma;Adam Steensberg<
Goldman Sachs Group Inc - Analyst

Lots to get through. And obviously, we're coming off the back of ADA. So maybe that's a good place to start. There are a few updates there, both with Survodutide and Petrelintide. Could you maybe just start with Survodutide because that was kind of the more the newer update that we got over the weekend?

And just provide your thoughts on the data.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot